About Trevi Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.trevitherapeutics.com/
Frequently Asked Questions
What is the 52-week range for TRVI?
The 52-week high is $20.22 and the 52-week low is $8.99.
What is the P/E ratio for TRVI?
The P/E ratio data is currently unavailable.
What is the dividend yield for TRVI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -23.59%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.76.
Analyst Recommendation Trends
Wall Street analyst consensus for TRVI over the last few months:
Latest TRVI News
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Trevi Therapeutics, Inc. (TRVI) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 4:50 PM EDTCompany ParticipantsJennifer Good -...
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value
Trevi Therapeutics has delivered very strong long term gains, yet the stock now screens as expensive on broad valuation checks. This raises questions about how much of the story is already in the price. The stock has returned roughly 10x over the past 5 years, which is an unusually large move that can leave less room for valuation mistakes. Upcoming presentations in 2026 on nalbuphine ER trial data may support confidence in the Trevi Therapeutics pipeline. Any disappointment in clinical...
Trevi Therapeutics to Participate in Upcoming September Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global He
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Heffernan Michael Thomas | -21,052 | - | - |
| 2026-09-15 | Heffernan Michael Thomas | -18,421 | - | - |
| 2026-09-15 | Heffernan Michael Thomas | -100 | $15.88 | $1,588 |
| 2026-09-15 | Heffernan Michael Thomas | -20,952 | $15.09 | $316,166 |
| 2026-09-15 | Heffernan Michael Thomas | +21,052 | $3.33 | $70,103 |
| 2026-09-15 | Heffernan Michael Thomas | -100 | $15.88 | $1,588 |
| 2026-09-15 | Heffernan Michael Thomas | -18,321 | $15.09 | $276,464 |
| 2026-09-15 | Heffernan Michael Thomas | +18,421 | $3.04 | $56,000 |
| 2026-06-03 | Heffernan Michael Thomas | +35,000 | - | - |
| 2026-06-03 | Meeker David P | +35,000 | - | - |
| 2026-06-03 | Mathers Edward T | +35,000 | - | - |
| 2026-06-03 | Colangelo Dominick | +35,000 | - | - |
| 2026-06-03 | VANLENT ANNE | +35,000 | - | - |
| 2026-02-19 | Simon Farrell | +160,000 | - | - |
| 2026-02-19 | Galletta Christopher | +35,000 | - | - |
| 2026-02-19 | Cassella James V | +215,000 | - | - |
| 2026-02-19 | SCIASCIA THOMAS | +85,000 | - | - |
| 2026-02-19 | GOOD JENNIFER L | +675,000 | - | - |
| 2026-01-08 | HASTINGS DAVID C | +375,000 | - | - |
| 2025-12-02 | Galletta Christopher | -4,225 | - | - |
| 2025-12-02 | Galletta Christopher | +4,225 | $0.511 | $2,159 |